Skip to main content

Practice

Smoking & Autoantibodies in Rheumatoid Arthritis

Investigators from the Netherlands have published their findings that smoking is a risk factor in rheumatoid arthritis (RA), led by the induction of local autoimmune responses at mucosal sites (in the lungs) and exemplified by RA-specific autoantibodies. 

RA is characterized by the

Read Article
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/EJkxX6aP56
Dr. John Cush @RheumNow( View Tweet )

Vitamin D Headlines (5.9.2025)

Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy. 

Read Article
Lupus QD Clinic - Polar Opposite Approaches for Lupus Dr. Eric Dein, Summit, New Jersey, presents SLE QD Clinic: Polar Opposite Approaches for Lupus. https://t.co/sGcYmo8gWs https://t.co/3hrYC6ATBy
Dr. John Cush @RheumNow( View Tweet )

Risk Factors for Knee Osteoarthritis

EurekAlert!

New research from the University of Sydney reveals that obesity, having a knee injury and occupational risks such as shift work and lifting heavy loads are primary causes of knee osteoarthritis.

Read Article
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/qs5f1qATKi
Dr. John Cush @RheumNow( View Tweet )

More Women with Autoimmune Diseases Die from Cardiovascular Disease

EurekAlert!

Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related to cardiovascular disease than men with the autoimmune diseases, according to new research published in the American Heart Association’s journal Circulation: 

Read Article

D-Lay Trial: High-Dose Vitamin D Retards Multiple Sclerosis

A randomized clinical trial with oral high-dose cholecalciferol ( vitamin D3) was shown to prevent or delay the onset of clinically isolated syndrome (CIS), typical for multiple sclerosis (MS).

Vitamin D plays an important role in immune

Read Article

Carpal Tunnel Syndrome as a Harbinger of Rheumatoid Arthritis

MedPage Today

Rates of carpal tunnel syndrome were significantly greater in patients later diagnosed with rheumatoid arthritis, according to a large, long-running observational study.

Read Article

Stable SLE - Should you Withdraw Immunosuppressant or Glucocorticoids?

An open-label, single-centre, randomized controlled trial tested whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in systemic lupus erythematosus (SLE) patients and found that IS withdrawal is noninferior to GC withdrawal in SLE patients in long-

Read Article
45 southern African American SLE pts compared to multiethnic cSLE, AA pts had signif higher Dz activity & greater damage accrual. Their mean SLICC score was 8.4, SLEDAI 13, but was 7.4 @6 mos & 4,7 @1 yr. They traveled an avg distance 75 miles to see Rheum https://t.co/R8WimzY0Az https://t.co/1lOJpjO2SY
Dr. John Cush @RheumNow( View Tweet )
"The most difficult thing is the decision to act, the rest is merely tenacity." –Amelia Earhart https://t.co/ANVIvID8qj
Dr. John Cush @RheumNow( View Tweet )
Complex Evolution of RA Management and Outcomes FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain. https://t.co/Vqe70WAijN
Dr. John Cush @RheumNow( View Tweet )

Keys to Mastery (5.2.2025)

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This month's campaign on Lupus is sponsored by Aurinia.

Read Article

Secondary Benefits to SGLT2 Inhibitor Use in SLE

An emulation trial of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in systemic lupus erythematosus patients yielded a significantly reduced risk of several cardiorenal complications among patients with SLE and type 2 diabetes.

Read Article
45 southern African American SLE pts compared to multiethnic cSLE, AA pts had signif higher Dz activity & greater damage accrual. Their mean SLICC score was 8.4, SLEDAI 13, but was 7.4 @6 mos & 4,7 @1 yr. They traveled an avg distance 75 miles to see Rheum https://t.co/NMlT4uo8jn https://t.co/uG5ofMGE6O
Dr. John Cush @RheumNow( View Tweet )
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Dr. John Cush @RheumNow( View Tweet )

RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?

Dr. John Cush @RheumNow( View Tweet )

Complex Evolution of RA Management and Outcomes

FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain.

Read Article

EULAR Guidelines on Reproductive Health

MedPage Today

Rheumatology patients considering or actually having babies can safely take most of the medications currently used to treat their conditions, according to an updated guideline from the European Alliance of Associations for Rheumatology (EULAR).

Read Article
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?

Dr. John Cush @RheumNow( View Tweet )

RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Dr. John Cush @RheumNow( View Tweet )

Gout pts No-Shows after ED: Study of 159 gout pts w/ gout flare & ED visit - only 56 (35%) had an outpatient visit addressing gout within 6 mos. Higher odds w/ being married (OR 2.66), no comorbidities (OR 3.86), colchicine use (OR 2.7), being older (OR 1.44) https://t.co/tAorjwf8xX
Dr. John Cush @RheumNow( View Tweet )

FDA Approves Rinvoq for Giant Cell Arteritis

Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology,

Read Article
×